Bioanalysis

  • Bioanalysis
  • Seamless Bioanalytical Transition from Preclinical to Clinical, and Beyond

     

    Seamless Bioanalytical Transition

    Altasciences’ scientists move in unison with you, collaboratively, accurately, and efficiently, from preclinical to clinical, and beyond. Our team of over 260 bioanalytical scientific veterans is strategically located across North America, and has experience with a wide spectrum of biological matrices in both animal and humans.
     
    Driven by your assay requirements, our program support includes LC-MS/MS, LBA OR HYBRID LBA/LC-MS/MS ASSAY platforms for:

    • Small molecules
    • Peptides
    • Proteins
    • Antibody-drug conjugates (ADC)
    • Monoclonal antibodies (mAb)
    • Immunogenicity
    • Anti-drug antibody
    • Neutralizing assays
    • Biomarkers — single or packages
    • Oligonucleotides

    Speak with a scientist

    Have 5 minutes? You may also be interested in the following:


    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

    Flow Cytometry — Integrated for Efficiency

     

    Altasciences’ preclinical and clinical sites share the same validation of instrumentation and panels to ensure a smooth transition. Our flow cytometry labs are located near our clinical pharmacology units, for rapid turnaround between sample collection and analysis.

    Preclinical Applications 
    • Immunotoxicology
    • Exposure confirmation (complement to PK evaluation) and on-target binding
    • Immunomodulation
    • Drug mechanism of action
    • Identification of potential biomarkers
    • Research/exploratory projects
    Clinical Applications 
    • Immunomodulation
    • Neutralization assays
    • PK/PD correlation
    • Receptor occupancy
    • Drug mechanism of action
    • Functional assays

    Let’s schedule a conversation to review your program needs.

    Speak with an expert

    You may also be interested in the following:


    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    One Integrated Solution for Meeting Your Preclinical to Clinical Drug Development Needs

    Multiplexed Cytokine Comparison Across Two Species Dosed with the Same Drug

    Detection of Plasma Cells and their Precursors in Bone Marrow and Peripheral Blood

    Evaluating Cytokine Data in Nonhuman Primate Safety Assessment Studies: A Correlation to Toxicity Outcomes

    COMPLIMENTARY WEBINAR ⁠— Cell-Based Assays

     

    Key Considerations for Developing
    Cell-Based Assays 

    In this complimentary webinar, Dr. Danielle Salha, Senior Director, Immunochemistry and Immunology, Ligand Binding Assays, discusses key parameters to consider during method development to support drug potency and immunogenicity characterization. 

    Topics covered:

    • Reducing development timelines and management of critical reagents
    • Important parameters to consider for NAb method development and for the development of potency assays
    • Management of critical reagents to support long-term clinical studies
    • Advantages of using the same method for both immunogenicity assessment and product characterization
    • Challenges that may be encountered when developing cell-based assays

    Watch now

    You may also be interested in the following:

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    ASOs — Expert Interviews, Case Studies, and More!

     

    It’s All About ASOs!

    Antisense oligonucleotides (ASOs) offer an exciting pathway to targeting the source of a disease’s pathogenesis. In this e-book, we take a deep dive into the bioanalytical development for the analysis of ASOs.

    Topics covered: 

    • Benefits and challenges of novel ASO bioanalytical approaches.
    • Case studies examining how best to align a bioanalytical technique with the goals of a particular ASO drug development program. 

    Download the FREE e-book now

    Speak with an expert.

    Have 5 minutes? Take a look at these:


    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    A Solution to Drive Your Drug Development Forward

     

    Nonclinical and Clinical Research Services — Phase I to IV

    Whether you are looking for a full-service solution or a stand-alone offering, Altasciences will help guide you along the way. We are accustomed to managing complex projects with different partners, and have robust communication and operational processes in place to ensure efficient integration.

    We offer a range of services for early phase and late phase studies, including:

    • Program Management
    • Clinical Monitoring
    • Scientific Publication Development and Review
    • Protocol Development and Medical Writing
    • PK/PD Analysis and Interpretation
    • Data Management
    • Biostatistics and Statistical Analysis
    • Support Services for Non-Clinical Studies

     

    Have 5 minutes? You may be interested in this:

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    How to Maximize Drug Development Success of Biologics

     

    Combining Trial Conduct and Bioanalysis for Success

    Combining Phase I trial conduct of biologics and bioanalysis is critical for successful drug development. Clinical development relies heavily on bioanalytical experts to generate critical data to understand pharmacokinetics and pharmacodynamics. 

    Here are just some of the benefits of working with Altasciences:

    • Timed interim sample analysis for dose escalation decisions
    • Rapid turnaround of PK/PD analysis between cohorts 
    • Biomarker development and validation for exploratory or primary endpoints
    • Proximity flow cytometry 
    • Centralized scheduling between clinic and lab
    • Ability to easily switch or combine platforms which are sensitive, have high throughput, and demonstrate exquisite specificity

    Watch this complimentary webinar to see how you can overcome challenges throughout all phases of drug development.

    Watch webinar

    Have 5 minutes? Take a look at these:


    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    Subscribe to Bioanalysis